Given that ccRCC is characterized as a “metabolism-related disease,” particularly in terms of lipid metabolism, the unexplored HIF-2α/LPCAT1/ACLY pathway may present a promising therapeutic target for controlling this tumor. The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.